Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• Antisense therapy targeting KIT mutations shows potential as SM treatment

  HT-KIT cut KIT protein levels by more than 80% and halted tumor growth in systemic mastocytosis (SM) models.

• COVID-19 booster triggers severe immune response in man with SM

  A patient with systemic mastocytosis suffered a life-threatening immune reaction after receiving an mRNA-1273 COVID-19 booster.

• New protein findings reveal clues to indolent systemic mastocytosis

  Results from a recent study could support more accurate diagnosis and future therapies in indolent systemic mastocytosis.

• New clinical trial set to evaluate dual-drug approach for SM with blood cancer

  A clinical trial is testing avapritinib and decitabine to improve outcomes for patients with SM and an associated blood cancer.

• New clinical trial seeks better treatment for indolent systemic mastocytosis

  The HARBOR study will compare elenestinib with a placebo and best supportive care to determine its effectiveness in treating ISM.

• AI predicts systemic mastocytosis risk using electronic health records

  AI models analyzed electronic health records to predict which patients may have undiagnosed systemic mastocytosis.

• Study finds TikTok videos on MCAS are filled with misinformation

  The study highlights the risks of relying on social media for medical advice.

• Case study: Mast cell leukemia’s rare presentation complicates diagnosis

  A recent case study describes how mast cell leukemia can present unusual symptoms that complicate diagnosis.

• New review analyzes bone disease in systemic mastocytosis

  Systemic mastocytosis (SM) can lead to severe osteoporosis, bone pain and fractures, requiring specialized treatment.

• Study urges early diagnosis and treatment of mast cell disorders to screen out SM

  Many cases of cutaneous mastocytosis remain confined to the skin, but some may indicate a risk for systemic mastocytosis (SM).